GEN inCode specializes in risk assessment and prediction of cardiovascular disease thrombosis and familial hypercholesterolemia. Cardiovascular disease (CVD) is a broad disease classification including coronary artery disease such as angina and myocardial infarction often referred to as heart attack. CVD also includes stroke, heart failure, hypertension and other vascular heart diseases and is the leading cause of death and disability worldwide accounting for 1 in every 4 deaths in the United States.

We are passionate about the genetics revolution in personalized medicine. We are committed to driving and supporting the incorporation of genetics in daily medical practice, through cooperation with health care professionals to improve the management of patients’ health in the areas of prevention, diagnosis, and treatment.

GEN inCode provides advanced genomic technology, products and recommendations fully validated by our scientific and clinical team. Our goal is to provide doctors and health care practitioners with advanced health information that combines both traditional clinical measures with a patient’s genetic information to provide a comprehensive risk assessment and clinical recommendation to help decision-making. Our technology helps select the optimal treatment pathway and informs and educates patients to become more aware of their cardiovascular risk helping patient adherence and empowerment to better manage their health.

GEN inCode technology and advanced genomic products provide information that helps patients and healthcare practitioners to assess and predict the onset of cardiovascular disease, thrombosis, and the diagnosis of Familial Hypercholesterolemia. Our online reporting system SITAB^® helps inform doctors of their patients’ health risk enabling patient behavioral and lifestyle changes alongside delivering the most effective therapies and treatment pathways.